Overview

A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast Cancer

Status:
Completed

Trial end date:
2011-05-01

Target enrollment:

Participant gender:

Summary

The aim of the study is to establish a feasible combination of bendamustine and paclitaxel in a weekly schedule. The two agents have different toxicity profiles and are well tolerated when given in a weekly fashion. The combination might be of special interest for elderly patients with hormone insensitive breast cancer

Phase:

Phase 1

Details

Lead Sponsor:

German Breast Group

Treatments:

Albumin-Bound Paclitaxel
Bendamustine Hydrochloride
Paclitaxel